Over the past five years, the stock has recorded a negative one-day return in 65% of cases, with a median decline of -2.4% ...

Jiangsu Hengrui Pharmaceuticals Co Ltd, a global pharmaceutical company focusing on scientific and technological innovation, announced on March 25 that it has entered into an exclusive license ...

Merck MRK will report its first-quarter 2024 earnings on April 24, before market open. The Zacks Consensus Estimate for first ...

Cantor Fitzgerald analyst Carter Gould initiated coverage of Merck (MRK) with a Neutral rating and $85 price target Shares have been “a ...

Merck is growing pharma sales and expanding margins, led by strong KEYTRUDA performance and cost discipline. Read more about ...

Merck (NYSE:MRK) entered into a non-exclusive license and option agreement with Cyprumed GmbH, aiming to enhance its peptide offerings through innovative oral delivery technology. Despite this ...

We recently published a list of 10 Best Pharma Stocks to Buy for Long Term Growth. In this article, we are going to take a ...

Sotatercept-csrk reduced the risk of major morbidity and mortality events in adults with WHO Group 1 PAH FC 3 or 4 at high risk of mortality.

Merck is holding strong among billionaire favorites, despite the broader healthcare sector dodging investor affection like a ...

We recently published a list of 10 Best Medical Stocks to Buy According to Billionaires. In this article, we are going to ...

Merck is juggling shareholder rebellion and market turbulence ahead of its annual meeting, with the company giving a firm thumbs-down to several investor proposals. This shareholder pushback adds a ...

Merck (NYSE:MRK) recently experienced a significant corporate governance event when multiple shareholder proposals were announced, with the company recommending against them for the upcoming annual ...